Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01335256 · ClinicalTrials.gov registry record · Phase 1
Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01335256 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 10 participants.
The verdict
NCT01335256, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Clinical study to determine safety, tolerability, and maximum tolerated dose of BAY1000394 given in 4 week on / 2 week off schedule to patients with advanced solid tumors
Interventions
- DRUG BAY1000394
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01335256
The ClinicalTrials.gov registry entry for NCT01335256 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BAY1000394 is the first listed.
NCT01335256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01335256 about?
NCT01335256 is a clinical study titled "Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies". Clinical study to determine safety, tolerability, and maximum tolerated dose of BAY1000394 given in 4 week on / 2 week off schedule to patients with advanced solid tumors
What is the current status of trial NCT01335256?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2010-12. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01335256?
The interventions under investigation include: BAY1000394 (DRUG).
Who is sponsoring clinical trial NCT01335256?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.